Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | MST1R | Q04912 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630955 | 0.92 | GRM4 (0.35) | GRM4DGAT1 | |
| SCHEMBL4356618 | 0.90 | GRM4 (0.34) | GRM4CYP2C9CYP2C8METKDR | |
| SCHEMBL2429376 | 0.90 | GRM4 (0.34) | GRM4CYP2C9CYP2C8METKDR | |
| SCHEMBL2429373 | 0.90 | GRM4 (0.34) | GRM4CYP2C9CYP2C8METKDR | |
| SCHEMBL4356621 | 0.90 | GRM4 (0.34) | GRM4CYP2C9CYP2C8METKDR | |
| SCHEMBL2433901 | 0.82 | GRM4 (0.36) | GRM4CYP2C9CYP2C8DGAT1PI4KB | |
| SCHEMBL2433905 | 0.82 | GRM4 (0.36) | GRM4CYP2C9CYP2C8DGAT1PI4KB | |
| SCHEMBL2433434 | 0.81 | GRM4 (0.36) | GRM4DGAT1 | |
| SCHEMBL2435334 | 0.81 | GRM4 (0.36) | GRM4DGAT1 | |
| SCHEMBL2432226 | 0.81 | GRM4 (0.36) | GRM4DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274655-A1 | 2-CARBOXY THIOPHENE DERIVATIVES AS ANTI VIRAL AGENTS | EIF2AK2, HAVCR2, GTF3C2 | GRM4 3141/4885CYP2C9 846/4885CYP2C8 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.